Stocks
Editas Medicine, Inc.EDIT
NASDAQHealthcareBiotechnology$2.44-3.94%
A clinical-stage biotechnology company developing gene-editing therapies using CRISPR/Cas9 and related technologies to treat inherited diseases. Its pipeline includes experimental treatments for genetic disorders, with research spanning ophthalmology, hematology, and other areas. Investors monitor t...
Market Cap: $238.8M52W Range: $0.91 – $4.54
Congressional Interest in Editas Medicine, Inc. (EDIT)
5 members of Congress have disclosed 18 trades in Editas Medicine, Inc. (EDIT), a Healthcare company. The buy/sell breakdown shows 10 purchases versus 8 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
18
Unique Politicians
5
Buys
10
Sells
8
Who in Congress Is Trading EDIT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |
| 2021-04-14 | Donald Sternoff Honorable Beyer | sell | $1K – $15K |